Aristides Capital LLC Invests $219,000 in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Aristides Capital LLC acquired a new stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 17,400 shares of the biotechnology company’s stock, valued at approximately $219,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in RCKT. Charles Schwab Investment Management Inc. raised its position in shares of Rocket Pharmaceuticals by 3.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 569,814 shares of the biotechnology company’s stock valued at $10,524,000 after buying an additional 20,322 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in Rocket Pharmaceuticals by 9.1% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 152,293 shares of the biotechnology company’s stock valued at $2,813,000 after acquiring an additional 12,680 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Rocket Pharmaceuticals by 9.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,767 shares of the biotechnology company’s stock worth $347,000 after purchasing an additional 1,675 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Rocket Pharmaceuticals by 1.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 119,633 shares of the biotechnology company’s stock worth $2,210,000 after purchasing an additional 1,561 shares during the last quarter. Finally, Verition Fund Management LLC purchased a new stake in shares of Rocket Pharmaceuticals in the third quarter valued at approximately $290,000. Hedge funds and other institutional investors own 98.39% of the company’s stock.

Rocket Pharmaceuticals Stock Down 7.9 %

NASDAQ:RCKT opened at $5.12 on Monday. Rocket Pharmaceuticals, Inc. has a 52 week low of $4.87 and a 52 week high of $26.98. The stock’s fifty day moving average is $9.16 and its two-hundred day moving average is $12.70. The stock has a market capitalization of $545.95 million, a price-to-earnings ratio of -1.86 and a beta of 1.00. The company has a quick ratio of 6.05, a current ratio of 6.05 and a debt-to-equity ratio of 0.06.

Rocket Pharmaceuticals (NASDAQ:RCKT) last posted its earnings results on Monday, March 3rd. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.06. Research analysts anticipate that Rocket Pharmaceuticals, Inc. will post -2.83 EPS for the current year.

Analyst Ratings Changes

RCKT has been the topic of a number of analyst reports. Wedbush assumed coverage on Rocket Pharmaceuticals in a research report on Monday, December 30th. They set an “outperform” rating and a $32.00 price objective on the stock. Chardan Capital dropped their price objective on shares of Rocket Pharmaceuticals from $62.00 to $54.00 and set a “buy” rating for the company in a report on Friday, February 28th. Jefferies Financial Group began coverage on shares of Rocket Pharmaceuticals in a research note on Wednesday, December 18th. They set a “buy” rating and a $29.00 target price on the stock. Scotiabank increased their price target on shares of Rocket Pharmaceuticals from $51.00 to $52.00 and gave the company a “sector outperform” rating in a research note on Monday, March 3rd. Finally, Needham & Company LLC reduced their price target on shares of Rocket Pharmaceuticals from $52.00 to $42.00 and set a “buy” rating on the stock in a research report on Friday, February 28th. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $43.00.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.